MNKD acquires SCPH for $5.35/sh cash +CVR—a 31% premium to Friday’s closing price: https://www.globenewswire.com/news-release/2025/08/25/3138369/29517/en/MannKind-to-Acquire-scPharmaceuticals-Accelerating-Revenue-Growth-and-Emerging-as-a-Patient-Centric-Leader-in-Cardiometabolic-and-Lung-Diseases.html The nominal deal value is $360M.